Indications for hematopoietic cell transplantation for lymphoproliferative blood diseases: current practice in Europe, 2022
Tsyapka O.M.1, Tushnytskyi O.M.1, Zalokotska L.V.1, Savuliak H.R.1, Kryachok I.A.2, Novak V.L.1
- 1Institute of Blood Pathology and Transfusion Therapy of the National Academy of Medical Sciences of Ukraine, Lviv, Ukraine
- 2Nonprofit Organization «National Cancer Institute», Kyiv, Ukraine
Summary. According to the European Society for Blood and Marrow Transplantation (The European Group for Blood & Marrow Transplantation — EBMT), the number of hematopoietic stem cell transplantations (HSCT) in Europe and other countries cooperating with EBMT is constantly growing and has reached almost 50 000. At the same time, more than half of the recipients who underwent HSCT are patients with lymphoid malignancies. There is a marked increase in cell therapy (CAR-T). In addition to the widespread adoption of HSCT technology, the most notable advances include the success of unrelated donor and haploidentical HSCT, the use of reduced-intensity high-dose chemotherapy (HDCT) in older patients, and the phenomenal growth in the use of cell therapy. In Ukraine, the deployment of the network of auto- and allotransplantation centers of hematopoietic stem cells (bone marrow) continues. This made it possible to significantly improve the availability of this type of highly specialized medical care, to introduce HSCT more widely into clinical practice, and allo-HSCT from relative and non-relative donors became available. Considering the active development of transplantation practices in Ukraine, the opening of new centers for transplantation of HSCT, it is urgent to conduct an analysis of screenings before transplantation, evaluate the effectiveness and improve the provision of medical care to patients with lymphoproliferative diseases.
Leave a comment